How lixisenatide slows or prevents damage to the kidneys in patients with type 2 diabetes and cardiovascular disease

October 3, 2018, Diabetologia

New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) and published simultaneously in The Lancet Diabetes & Endocrinology shows how the glucose-lowering drug lixisenatide can slow or prevent damage to the kidneys in macro-albuminuric patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease. The study is presented by Dr. Marcel Muskiet, Amsterdam University Medical Centers, location VUMC, Amsterdam, The Netherlands, and colleagues. The study will be published online by The Lancet Diabetes & Endocrinology at the embargo time.

In the ELIXA trial, lixisenatide, a short-acting glucagon-like peptide 1 receptor agonist (GLP-1RA), demonstrated cardiovascular safety versus placebo in T2DM . In this follow-up study, the authors investigated the effect of lixisenatide on renal outcomes —T2DM patients with a recent coronary artery event were assigned to lixisenatide (10-20 μg) or placebo, on top of standard of care.

The secondary endpoint percent change in urinary albumin-to-creatinine ratio (UACR—a measure of kidney damage) from baseline to Week 108 was modestly lower with lixisenatide vs. placebo (24% vs. 34%) in the overall population, as previously reported.

Here, in a partly pre-specified and partly exploratory analysis in the intention to treat (ITT) population of ELIXA, the authors investigated progression of UACR and the glomerular filtration rate (eGFR —a measure of kidney function) according to pre-specified baseline UACR categories (normoalbuminuria: UACR < 30 mg/g; microalbuminuria: UACR >30 to <300 mg/g; and macroalbuminuria: UACR >300 mg/g). Time to new onset macroalbuminuria and doubling of serum creatinine were also determined.

Between July 2010 and August 2013, 6068 patients were enrolled. Baseline UACRs were available in 5978 (99%) of patients with median follow-up time of 25 months. At baseline, 74% had normoalbuminuria, 19% microalbuminuria, and 7% macroalbuminuria. After 108 weeks, the difference in percentage reduction in UACR (lixisenatide vs. placebo) was -1·7% (non-statistically-significant) in patients with normoalbuminuria, -21·1% (borderline statistically significant) in patients with microalbuminuria and -39·2% (statistically significant) in patients with macroalbuminuria.

Furthermore, lixisenatide was associated with a borderline statistically significant 16% reduction in risk of incidence of macroalbuminuria. The eGFR declined throughout the study across all albuminuria categories, with the largest decrease in the macroalbuminuric subgroup. There were no significant differences in eGFR decline between treatment arms in the overall population or in UACR subgroups.

The authors conclude: "On the basis of available evidence, GLP-1RAs reduce UACR across the range of eGFR (CKD stages 1-4), particularly in patients with macroalbuminuria at baseline. It can be speculated that direct GLP-1 receptor activation in the kidney, or multiple anti-inflammatory and anti-oxidative stress effects, may contribute to the suggested renal benefits of GLP-1RAs. The effect of GLP-1RAs on eGFR decline and hard renal endpoints remains equivocal, and should be investigated in dedicated renal outcome studies with longer follow-up time in T2DM patients with more advanced CKD at baseline."

Explore further: Saxagliptin linked to improved albumin/creatinine ratios

Related Stories

Saxagliptin linked to improved albumin/creatinine ratios

October 25, 2016
(HealthDay)—For patients with type 2 diabetes, saxagliptin is associated with improvement in the albumin/creatinine ratio (ACR), according to a study published online Oct. 17 in Diabetes Care.

CVD biomarkers respond better to Telmisartan than non-ARB blood pressure meds

August 31, 2015
When it comes to treating high blood pressure, not all anti-hypertensive medications are equal, and results of the ATTEMPT-CVD trial suggest that telmisartan, an angiotensin II receptor blocker (ARB) might have benefits over ...

Reduced eGFR, increased UACR linked to incident A-fib

August 11, 2017
(HealthDay)—Reduced estimated glomerular filtration rate (eGFR) and elevated urine albumin-to-creatinine ratio (UACR) are associated with increased risk of incident atrial fibrillation (AF), according to research published ...

Albuminuria predicts cardiovascular outcome after PCI

February 17, 2016
(HealthDay)—An elevated urinary albumin excretion rate can predict adverse cardiovascular outcomes in patients undergoing elective percutaneous coronary intervention, according to a study published in the March 1 issue ...

Gestational diabetes may indicate future subclinical renal issues

May 10, 2018
(HealthDay)—Gestational diabetes mellitus (GDM) may be an early indicator of subsequent subclinical renal dysfunction, according to a study published online May 4 in Diabetes Care.

ELIXA trial shows CV safety of Lixisenatide

August 31, 2015
In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the ...

Recommended for you

Does diabetes damage brain health?

December 14, 2018
(HealthDay)—Diabetes has been tied to a number of complications such as kidney disease, but new research has found that older people with type 2 diabetes can also have more difficulties with thinking and memory.

Researchers study abnormal blood glucose levels of discharged patients

December 14, 2018
University of Minnesota Medical School researchers decided to delve into an area where little data currently exists. They wanted to know what happens after these patients with abnormal blood glucose measurements are discharged? ...

Researchers zero in on potential therapeutic target for diabetes, associated diseases

December 14, 2018
A recent study led by researchers in Texas A&M University's department of nutrition and food science shows how a novel regulatory mechanism serves as an important biomarker for the development of diabetes, as well as a potential ...

Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes

December 11, 2018
Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes.

Millions of low-risk people with diabetes may be testing their blood sugar too often

December 10, 2018
For people with Type 2 diabetes, the task of testing their blood sugar with a fingertip prick and a drop of blood on a special strip of paper becomes part of everyday life.

Very low calorie diets trialled by NHS to tackle diabetes

December 7, 2018
Hundreds of thousands of people will receive NHS help to battle obesity and type 2 diabetes under radical action set out by Simon Stevens, Chief Executive of NHS England.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.